Effects of suppressing GAB2 expression. (A) Suppression of GAB2 by two independent GAB2-specific shRNAs, shGAB2 #6 and shGAB2 #7, in ovarian cancer cell lines NIH:OVCAR3 and FUOV1. (B) Effects of suppressing GAB2 expression on cell proliferation in a panel of ovarian, lung, and breast cancer cell lines that include high-expressing (NIH:OVCAR3, FUOV1, IGROV1, COV-362, NCI-H1435) and low-expressing (MDA-MB-453) cell lines. Statistically significant P values for cells expressing shGAB2 #6 (*) and shGAB2 #7 (**) compared with shLacZ control for each cell line are the following: NIH:OVCAR3, *P < 0.0001 and **P < 0.0001; IGROV1, *P < 0.0001 and **P < 0.0001; FUOV1, *P < 0.05 and **P < 0.0001; OV-56, shGAB2 #6 P < 0.0001 and shGAB2 #7 P = 0.8617; MD-MB-453, shGAB2 #6 P = 0.9847 and shGAB2 #7 P = 0.708 calculated by unpaired t test. (C) MAPK/ERK and PI3K pathway status following suppression of GAB2. GAB2*, GAB2 overexpressing; ns, not significant; PIK3CA*, PIK3CA mutant.